Sr. Scientist, Biology at AstraZeneca

Hamilton, Ontario, Canada -

Full Time

Start Date

Immediate

Expiry Date

25 Apr, 26

Salary

163612.0

Posted On

25 Jan, 26

Experience

5 year(s) or above

Remote Job

Yes

Telecommute

Yes

Sponsor Visa

Skills

Cancer Biology, Radiation Biology, Cancer Cell Culture, In Vitro Bioassays, Combination Drug Testing, Molecular Assays, Histology Assays, Cytotoxicity Assays, Flow Cytometry, ELISA, Western Blotting, IHC, Efficacy Studies, Problem Solving, Communication, Collaboration

Industry

Pharmaceutical Manufacturing

Description

Fusion Pharmaceuticals, a member of the AstraZeneca Group, is a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion’s clinical portfolio includes but is not limited to: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; and FPI-2068, a bispecific IgG-based EGFR-cMET targeted radioconjugate currently in a Phase 1 trial. Fusion has multiple other pipeline programs that will soon be entering into early FIH trials. In addition, Fusion is pursuing combination programs between RCs and other therapeutic modalities including DNA Damage Response Inhibitors (DDRis) and immune-oncology agents. To support execution for these programs, Fusion has a fully operational Good Manufacturing Practice (GMP) compliant state-of-the-art radioconjugate manufacturing facility to meet supply demand for our growing pipeline of RCs. Responsibilities Independent technical lead for radio conjugate (RC) research programs in oncology, driving strategy and execution from concept to decision points Apply creative thinking and scientific expertise to understand RC biology such as mechanisms of action, determinants of drug sensitivity and resistance, and rational combination strategies Collaborate closely with cross‑functional internal teams and external partners by setting clear objectives, delivering robust data packages, and communicating results to agreed timelines Present program updates and scientific results at internal governance meetings, project team forums, and external scientific conferences Qualifications: Ph.D. in a cancer of radiation biology (or closely related field) with 3+ years of relevant work experience Strong knowledge of cancer and/or radiation biology, with a demonstrated commitment to continued learning Expertise in cancer cell culture, development & technical validation of fit-for-purpose in vitro bioassays, and combination drug testing Proficiency with molecular and histology assays, including cytotoxicity assays, receptor binding and internalization, flow cytometry, ELISA, Western blotting and IHC Experience designing and interpreting efficacy studies in mouse cancer model is an asset Proven ability to thrive in a fastpaced, evolving research environment with strong problemsolving and prioritization skills Excellent verbal and written communication, with a track record of clear data presentation and scientific storytelling Experience working in multidisciplinary, collaborative teams and communicating effectively with colleagues at all levels Ability to partner and manager external CRO’s is an asset Experience with safe handling of radioactive and biohazardous materials is an asset Fusion Pharmaceuticals is an equal opportunity employer that is committed to inclusive, barrier-free recruitment and selection processes, if contacted for an interview, please advise Human Resources if you require accommodation. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran Annual base salary for this position ranges from $109,075.30 to $163,612.80. Fusion Pharmaceuticals, a member of Astra Zeneca PLC, is committed to providing fair and equitable compensation opportunities to all colleagues. Our compensation policies and practices have been designed to allow colleagues to progress through the salary range over time as they progress in their role. The range provided in this posting represents an offer pay range used in a majority of situations. The base pay offered will vary depending on multiple individualized factors, including the candidate's skills and experience, job-related knowledge, and other specific business and organizational needs. In some cases, offers outside the range may also be considered to address unique circumstances. In addition, our permanent positions offer an annual Variable Pay Bonus/Short Term Incentive opportunity as well as eligibility to participate in our equity-based long term incentive program (in applicable to the role). Benefits offered for permanent roles include a competitive Flex Benefits & Retirement Savings Program, 4 weeks paid vacation, and annual Personal Days. Fixed Term Contract/Temporary positions (excluding students) are offered a Contract Benefits Program. Date Posted 23-Jan-2026 Closing Date 31-Jan-2026 AstraZeneca embraces diversity and equality of opportunity. We are committed to building an inclusive and diverse team representing all backgrounds, with as wide a range of perspectives as possible, and harnessing industry-leading skills. We believe that the more inclusive we are, the better our work will be. We welcome and consider applications to join our team from all qualified candidates, regardless of their characteristics. We comply with all applicable laws and regulations on non-discrimination in employment (and recruitment), as well as work authorization and employment eligibility verification requirements.

Responsibilities

The Sr. Scientist will lead radio conjugate research programs in oncology, driving strategy and execution from concept to decision points. They will collaborate with internal teams and external partners, presenting program updates and scientific results at various forums.